Has Mario Goessl, MD received payments from drug or device companies?

Yes. Drug and device makers reported $62,068 in general payments to Mario Goessl, MD across 117 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mario Goessl, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mario Goessl, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mario Goessl, MD

Cardiovascular Disease · Minneapolis, MNNPI 1194846964

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $45,863 of the $62,068 with a category attached, or 73.9%. 7 manufacturers reported payments, led by Abbott at 59.6% of the total. Reporting peaked in 2020 at $15,259 and has fallen 84.8% since, to $2,324 in 2025. Among cardiovascular disease clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$62,068in general payments, 2019–2025

Across 117 payments — averaging $530.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$37K
Edwards Lifesciences$12K
Boston Scientific$6K
Medtronic$4K
Livanova USA, Inc.$4K
Philips North America LLC$22
plus $12 from 1 others

$710,744in research payments, 2019–2025

Across 224 payments — averaging $3172.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Edwards Lifesciences$194K
GE HealthCare$157K
Abbott$157K
Boston Scientific$84K
Livanova USA, Inc.$59K
W. L. Gore & Associates, Inc.$35K
plus $25K from 2 others

What the payments were for

Consulting fees$45,86374%
Speaking & faculty fees$9,85016%
Travel & lodging$1,4432%
Food & beverage$4,9018%
Education$120%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	54	$36,988
Edwards Lifesciences	32	$11,961
Boston Scientific	14	$5,532
Medtronic(2 entities)	10	$3,836
Livanova USA, Inc.	5	$3,718
Philips North America LLC	1	$22
Chiesi USA, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Tendyne Mitral Valve System$13,513
COREVALVE EVOLUT R$3,578
TMVR$3,563
Watchman$3,342
MitraClip System$3,000
GENERAL VASCULAR ACCESS$1,500
Mitra Clip system$651
MitraClip$404
WATCHMAN Access System$226
SAPIEN 3 Ultra RESILIA$180
CARDIOMEMS$143
SYNERGY$135
Edwards SAPIEN XT Transcatheter Heart Valve$126

How this compares

$62,068 in reported general payments places this provider in the 90th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota →

Medicare billing

Part B allowed, 2024

$137,580

Medicare patients

334

Services billed

705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	18	$22,261
Metoprolol Succinate	45	$660
Rosuvastatin Calcium	26	$344
Losartan Potassium	33	$235
Atorvastatin Calcium	22	$183
Carvedilol	20	$146
Metoprolol Tartrate	24	$126
Amlodipine Besylate	15	$51

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Minneapolis

Jeffrey ChambersMinneapolis$3.2M
Markus MeyerMinneapolis$786K
Robert SchwartzMinneapolis$502K
Robert VantasselMinneapolis$493K
Nedaa SkeikMinneapolis$453K
Joao CavalcanteMinneapolis$384K
Inderjit AnandMinneapolis$384K
David HurrellMinneapolis$205K
Yader Sandoval PichardoMinneapolis$157K
Charles HerzogMinneapolis$157K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →